Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -48.9x - -54.0x | -51.4x |
| Selected Fwd P/E Multiple | 3.4x - 3.8x | 3.6x |
| Fair Value | ₩39,380 - ₩43,525 | ₩41,453 |
| Upside | 4.6% - 15.6% | 10.1% |
| Benchmarks | - | Full Ticker |
| Komipharm International Co., Ltd. | - | KOSDAQ:A041960 |
| Oscotec Inc. | - | KOSDAQ:A039200 |
| ADBiotech Co., Ltd. | - | KOSDAQ:A179530 |
| WooGene B&G Co., Ltd | - | KOSDAQ:A018620 |
| Tdspharm Co., Ltd. | - | KOSDAQ:A464280 |
| Mezzion Pharma Co.,Ltd. | - | KOSDAQ:A140410 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| A041960 | A039200 | A179530 | A018620 | A464280 | A140410 | |||
| KOSDAQ:A041960 | KOSDAQ:A039200 | KOSDAQ:A179530 | KOSDAQ:A018620 | KOSDAQ:A464280 | KOSDAQ:A140410 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | 30.1% | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | 21.7% | NM- | ||
| Latest Twelve Months | 19.5% | 101.6% | 40.8% | -637.5% | -25.4% | -160.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -9.5% | -329.6% | -35.5% | -3.8% | 12.9% | -96.7% | ||
| Prior Fiscal Year | -9.3% | -490.4% | -27.3% | -2.0% | 15.6% | -40.1% | ||
| Latest Fiscal Year | 22.3% | 2.6% | -71.4% | -9.4% | 13.5% | -226.2% | ||
| Latest Twelve Months | 20.6% | 1.1% | -34.9% | -9.4% | 12.9% | -271.9% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 64.3x | -1018.8x | -14.9x | 19.5x | 10.1x | -94.4x | ||
| Price / LTM Sales | 7.2x | 35.8x | 3.0x | 0.5x | 2.3x | 143.8x | ||
| LTM P/E Ratio | 95.6x | 3238.6x | -8.7x | -5.6x | 17.9x | -49.1x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -8.7x | 17.9x | 3238.6x | |||||
| Historical LTM P/E Ratio | -310.4x | -59.9x | -14.1x | |||||
| Selected P/E Multiple | -48.9x | -51.4x | -54.0x | |||||
| (x) LTM Net Income | (23,090) | (23,090) | (23,090) | |||||
| (=) Equity Value | 1,128,237 | 1,187,618 | 1,246,999 | |||||
| (/) Shares Outstanding | 30.1 | 30.1 | 30.1 | |||||
| Implied Value Range | 37,464.49 | 39,436.30 | 41,408.12 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 37,464.49 | 39,436.30 | 41,408.12 | 37,650.00 | ||||
| Upside / (Downside) | -0.5% | 4.7% | 10.0% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | A041960 | A039200 | A179530 | A018620 | A464280 | A140410 | |
| Value of Common Equity | 392,190 | 1,247,119 | 35,263 | 28,223 | 58,618 | 1,133,824 | |
| (/) Shares Outstanding | 71.0 | 38.3 | 12.6 | 28.9 | 5.5 | 30.1 | |
| Implied Stock Price | 5,520.00 | 32,600.00 | 2,800.00 | 977.00 | 10,600.00 | 37,650.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 5,520.00 | 32,600.00 | 2,800.00 | 977.00 | 10,600.00 | 37,650.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |